A recent report has suggested that future patent expires in the cardiac and anti-diabetes space would form a good opportunity for smaller firms, given their franchise in these segments.
The world's biggest drug maker Pfizer Inc has offered about Rs 680 crore to raise its stake in its Indian subsidiary to 75 per cent from 41 per cent. The offer of Rs 675 per share, however, is unlikely to find takers, since Pfizer share price rose 10.02 per cent to close at Rs 685.4 per share on the Bombay Stock Exchange (BSE) on Monday, analysts feel.
358 of 413 drug patent applications for the disease in India are from top multinationals. An analysis of pharma patent applications pending with the patent office by the group, which did not wish to be identified, has put the number of cancer drug patent applications at 413. Of these, 358 came from top multinationals like Novartis, Aventis, Bristol Myers Squibb, Pfizer, Boehringer, Roche and Abbot.
Even as some major global pharmaceutical majors like Novartis say India's patent laws are weak and a hurdle to their investment plans for the country
The resultant price increase was the cause of a surprise upward variation in the "drug and medicines" segment of the weekly wholesale price index of the ministry of commerce and Industry last week, it is learnt.
This has prompted public health groups to call the concerns of Swiss drug major Novartis that inadequacies in Indian patent law will have negative consequences for patients and public health in India as 'bogus'.
The Indian government is planning to make testing of seeds compulsory for private seed makers like Monsanto, Bayer and Novartis in the country.
Abbott Laboratories is suing India's Ranbaxy Laboratories as well as Israel's Teva and Sandoz of the Novartis group, in Chicago for allegedly violating its patents protecting Omnicef, a drug used to treat ear, throat and skin infections.
Sipika Singh switched careers from being a senior consultant with Ernst and Young to a regional marketing role in the pharma major, Novartis in Singapore.
India's biggest drug maker Ranbaxy Laboratories Ltd has put in its bid to acquire generic business of German pharmaceutical firm Merck.
20 CEOs are from the companies based in US.
An insider said that over the past decade or so Cipla has become immune to the exits of leaders. There have been no directional change in the long-term strategies.
NPPA suggests expanding the list of essential medicines whose prices are controlled
Data exclusivity key building block for R&D investment, says Novartis.
Most foreign drug makers have 100% subsidiaries in India, apart from their listed arms.
SAS, global leaders in business intelligence solutions, on Friday announced setting up of its largest research and development centre in Pune, as it expects the Indian market to grow by 27 per cent and generate $87.4 billion worth business by 2009.
Investors must carefully watch the developments on the MNC pipeline.
Morepen Laboratories is all set to gain from the 180-day marketing exclusivity granted to Geneva Pharmaceuticals Inc for Loratadine in the U S.
Broader markets are outperforming the benchmark indices- BSE Midcap and Smallcap indices are up 0.8%-1%.
India had been engaged in a contentious battle with the US over the issue, especially in the pharmaceutical sector.
Ohm Laboratories Inc, a wholly-owned subsidiary of Ranbaxy has received approval from the US Food and Drug Administration for manufacturing and marketing Valsartan tablets in strengths of 40 mg, 80 mg, 160 mg, and 320 mg on an exclusive basis, Ranbaxy Laboratories said in a statement.
At least two key drugs in the gliptin category have already gone off patent and cheaper variants are crowding the market. Also, several patent expiries are round the corner for the newest category of drugs - SGLT-2 inhibitors or gliflozins.
Industry fears tougher US stance on IP after President Donald Trump asserted that foreign countries must pay a fair share for drug development costs. Aneesh Phadnis reports.
Kamil's elder sister Samina Vaziralli has taken on an expanded role
The letter was the latest sign of US frustration about the business environment in India.
Irrespective of demonetisation and GST blues, IIM Lucknow has been able to successfully place their batch of 459 students.
Sun Pharma and Dr Reddy's top list in terms of those who face most class-action litigation
A certain segment of the US pharma industry have become vocal about Indian policies on domestic content requirements and IPR.
After spending considerable time and energy in remediation efforts in the wake of the US Food and Drug Administration's warning letter on compliance issues, the company's leadership has finally set out to bring the house in order.
Nearly 150 companies visited the campus this year.
The company now plans to bet on health sciences, skin care and specialised products, says Arnab Dutta.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances